Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: 'Positive News' Imminent From Oxford and AstraZeneca Vaccine

Plus: Favipiravir Price Cut And New Approval In India

Executive Summary

More news from across the sector, including Novartis's non-profit pledge on medicines and Zydus Cadila commencing Phase I vaccine trial.

You may also be interested in...



Coronavirus Update: Roche's Actemra Fails In Phase III COVID Study

Disappointment as Roche/Chugai antibody tocilizumab misses most endpoints. 

Coronavirus Update: Vaccine Companies To Update Lawmakers As Crisis Deepens In US

Executives from Moderna, Pfizer and AstraZeneca and others will give politicians in Washington DC an update on the progress of their vaccine - but will resist pressure to make promises of a breakthrough in 2020.

UK MHRA Relies On Remote Drug GMP Inspections As COVID-19 Pandemic Grounds Inspectors

Experience from previous viral outbreaks has allowed the UK agency to move quickly; long-term focus is on hybrid inspection approach.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel